Avelos Therapeutics

Developer of biomarker-driven anti-cancer targeted therapies

placeGangseo, Yeongnam, South Korea calendar_todayFounded 2021 groups15 employees language avelostx.com

Innovation

8 patent families — focus: Human necessities, Chemistry & metallurgy; filing pace accelerating. Cited 37 times.

YearFilings
20221
20231
20244
20255
20266

Investor mix

13 investors on record; lead investors include QUAD, Time Polio Asset Management, Mirae Asset Capital Markets, Mirae Asset.

Investor typeCountShare
Venture capital538%
Private equity18%
Bank & private debt323%
Other / undisclosed431%
Coming soon